Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
Phase 2
Completed
- Conditions
- Worsening Heart Failure (WHF)Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT06264310
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
🇺🇸Piedmont Hospital Transplant, Atlanta, Georgia, United States
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Phase 2
Recruiting
- Conditions
- Hepatorenal SyndromeAcute Kidney Injury
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 95
- Registration Number
- NCT05875948
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Piedmont Healthcare, Inc, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
News
No news found